Resveratrol, a sirtuin 1 activator, increases IL-6 production by peripheral blood mononuclear cells of patients with knee osteoarthritis

详细信息    查看全文

• 作者：Daniel Wendling (1) (2)
  Wasim Abbas (2)
  Marie Godfrin-Valnet (1)
  Xavier Guillot (1)
  Kashif Aziz Khan (2)
  Jean-Pierre Cedoz (1)
  Lucile Baud (2)
  Clément Prati (1)
  Georges Herbein (2) (3)
  
• 关键词：IL ; 6 ; Osteoarthritis ; PBMCs ; Resveratrol ; Sirtuin 1
• 刊名：Clinical Epigenetics
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：5
• 期：1
• 全文大小：381KB
• 参考文献：1. Reynard LN, Loughlin J: Genetics and epigenetics of osteoarthritis. / Maturitas 2012, 71:200-04. CrossRef
  2. Gabay O, Sanchez C: Epigenetics, sirtuins and osteoarthritis. / Joint Bone Spine 2012, 79:570-73. CrossRef
  3. Herbein G, Wendling D: Histone deacetylases in viral infections. / Clin Epigenetics 2010, 1:13-4. CrossRef
  4. Taylor DM, Maxwell MM, Luthi-Carter R, Kazantsev AG: Biological and potential therapeutic roles of sirtuin deacetylases. / Cell Mol Life Sci 2008, 65:4000-018. CrossRef
  5. Zeng L, Chen R, Liang F, Tsuchiya H, Murai H, Nakahashi T, Iwai K, Takahashi T, Kanda T, Morimoto S: Silent information regulator, Sirtuin 1, and age-related diseases. / Geriatr & Gerontol Int 2009, 9:7-5. CrossRef
  6. Gabay O, Oppenhiemer H, Meir H, Zaal K, Sanchez C, Dvir-Ginzberg M: Increased apoptotic chondrocytes in articular cartilage from adult heterozygous SirT1 mice. / Ann Rheum Dis 2012, 71:613-16. CrossRef
  7. Takayama K, Ishida K, Matsushita T, Fujita N, Hayashi S, Sasaki K, Tei K, Kubo S, Matsumoto T, Fujioka H, Kurosaka M, Kuroda R: SIRT1 regulation of apoptosis of human chondrocytes. / Arthritis Rheum 2009, 60:2731-740. CrossRef
  8. Gagarina V, Gabay O, Dvir-Ginzberg M, Lee EJ, Brady JK, Quon MJ, Hall DJ: SirT1 enhances survival of human osteoarthritic chondrocytes by repressing protein tyrosine phosphatase 1B and activating the insulin-like growth factor receptor pathway. / Arthritis Rheum 2010, 62:1383-392. CrossRef
  9. Fujita N, Matsushita T, Ishida K, Kubo S, Matsumoto T, Takayama K, Kurosaka M, Kuroda R: Potential involvement of SIRT1 in the pathogenesis of osteoarthritis through the modulation of chondrocyte gene expressions. / J Orthop Res 2011, 29:511-15. CrossRef
  10. Dvir-Ginzberg M, Gagarina V, Lee EJ, Booth R, Gabay O, Hall DJ: Tumor necrosis factor alpha-mediated cleavage and inactivation of SirT1 in human osteoarthritic chondrocytes. / Arthritis Rheum 2011, 63:2363-373. CrossRef
  11. Villalba JM, Alcain FJ: Sirtuin activators and inhibitors. / Biofactors 2012, 38:349-59. CrossRef
  12. Lei M, Wang JG, Xiao DM, Fan M, Wang DP, Xiong JY, Chen Y, Ding Y, Liu SL: Resveratrol inhibits interleukin 1β-mediated inducible nitric oxide synthase expression in articular chondrocytes by activating SIRT1 and thereby suppressing nuclear factor-κB activity. / Eur J Pharmacol 2012, 674:73-9. CrossRef
  13. Wang J, Gao JS, Chen JW, Li F, Tian J: Effect of resveratrol on cartilage protection and apoptosis inhibition in experimental osteoarthritis of rabbit. / Rheumatol Int 2012, 32:1541-548. CrossRef
  14. Csiszar A, Labinskyy N, Pinto JT, Ballabh P, Zhang H, Losonczy G, Pearson K, de Cabo R, Zhang C, Ungvari Z: Resveratrol induces mitochondrial biogenesis in endothelial cells. / Am J Physiol Heart Circ Physiol 2009, 297:H13-H20. CrossRef
  15. Zhu X, Liu Q, Wang M, Liang M, Yang X, Xu X, Zou H, Qiu J: Activation of Sirt1 by resveratrol inhibits TNF-α induced inflammation in fibroblasts. / PLoS One 2011, 6:e27081. CrossRef
  16. Fusco S, Maulucci G, Pani G: Sirt1: def-eating senescence? / Cell Cycle 2012, 11:4135-146. CrossRef
  17. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW: Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. / EMBO J 2004, 23:2369-380. CrossRef
  18. Ashburner BP, Westerheide SD, Baldwin AS Jr: The p65 (RelA) subunit of NF-κB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. / Mol Cell Biol 2001, 21:7065-077. CrossRef
  19. Chae HJ, Ha KC, Lee GY, Yang SK, Yun KJ, Kim EC, Kim SH, Chae SW, Kim HR: Interleukin-6 and cyclic AMP stimulate release of cathepsin B in human osteoblasts. / Immunopharmacol Immunotoxicol 2007, 29:155-72. CrossRef
  20. Gabay O, Sanchez C, Dvir-Ginzberg M, Gagarina V, Zaal KJ, Song Y, He XH, McBurney MW: Sirtuin 1 enzymatic activity is required for cartilage homeostasis in vivo in a mouse model. / Arthritis Rheum 2013, 65:159-66. CrossRef
  21. Kotas ME, Gorecki MC, Gillum MP: Sirtuin-1 is a nutrient-dependent modulator of inflammation. / Adipocyte 2013, 2:113-18. CrossRef
  22. Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B, Ido Y, Lan F, Walsh K, Wierzbicki M, Verbeuren TJ, Cohen RA, Zang M: SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. / J Biol Chem 2008, 283:20015-0026. CrossRef
  23. Fernandes CA, Fievez L, Neyrinck AM, Delzenne NM, Bureau F, Vanbever R: Sirtuin inhibition attenuates the production of inflammatory cytokines in lipopolysaccharide-stimulated macrophages. / Biochem Biophys Res Commun 2012, 420:857-61. CrossRef
  24. Niederer F, Ospelt C, Brentano F, Hottiger MO, Gay RE, Gay S, Detmar M, Kyburz D: SIRT1 overexpression in the rheumatoid arthritis synovium contributes to proinflammatory cytokine production and apoptosis resistance. / Ann Rheum Dis 2011, 70:1866-873. CrossRef
  25. Roger T, Lugrin J, Le Roy D, Goy G, Mombelli M, Koessler T, Ding XC, Chanson AL, Reymond MK, Miconnet I, Schrenzel J, Fran?ois P, Calandra T: Histone deacetylase inhibitors impair innate immune response to Toll-like receptor agonists and to infection. / Blood 2011, 117:1205-217. CrossRef
  26. Mombelli M, Lugrin J, Rubino I, Chanson AL, Giddey M, Calandra T, Roger T: Histone deacetylase inhibitors impair antibacterial defenses of macrophages. / J Infect Dis 2011, 204:1367-374. CrossRef
  27. Kang OH, Jang HJ, Chae HS, Oh YC, Choi JG, Lee YS, Kim JH, Kim YC, Sohn DH, Park H, Kwon DY: Anti-inflammatory mechanisms of resveratrol in activated HMC-1 cells: pivotal roles of NF-κB and MAPK. / Pharmacol Res 2009, 59:330-37. CrossRef
  28. Dvir-Ginzberg M, Steinmeyer J: Towards elucidating the role of Sirt1 in osteoarthritis. / Front Biosci 2013, 18:343-55. CrossRef
  
• 作者单位：Daniel Wendling (1) (2)
  Wasim Abbas (2)
  Marie Godfrin-Valnet (1)
  Xavier Guillot (1)
  Kashif Aziz Khan (2)
  Jean-Pierre Cedoz (1)
  Lucile Baud (2)
  Clément Prati (1)
  Georges Herbein (2) (3)
  
  1. Department of Rheumatology, CHRU de Besan?on, Boulevard Fleming, F-25030, Besan?on, France
  2. EA 4266, Pathogens & Inflammation Laboratory, SFR FED4234, Université de Franche-Comté, Besan?on, France
  3. Department of Virology, CHRU de Besan?on, 2 Place Saint-Jacques, F-25030, Besan?on, France
  
• ISSN：1868-7083

文摘

Background Sirtuin 1 (Sirt1) is a nuclear enzyme from the class III histone deacetylases that modulates gene expression and is involved in bone and cartilage remodeling. The goal of our study was to evaluate Sirt1 activity in peripheral blood mononuclear cells in patients with osteoarthritis in comparison with control patients, and to determine the relationship between Sirt1 activity and production of TNFα, IL-6 and IL-8 by peripheral blood mononuclear cells after ex vivo treatment with resveratrol, a Sirt1 activator. Results A prospective study was performed to compare the activity of Sirt1 in patients with primary osteoarthritis of the knee (American College of Rheumatology criteria) with its activity in controls. Peripheral blood mononuclear cells were isolated from peripheral blood, and Sirt1 activity evaluated from cytoplasmic and nuclear compartments using a fluorometric assay. Culture supernatant levels of TNFα, IL-6, and IL-8 were quantified before and after resveratrol ex vivo treatment. Nineteen patients with symptomatic knee osteoarthritis (age 64 ±9 years) and 18 controls (age 54 ±13 years) were included. No differences were found in cytoplasmic or nuclear Sirt1 activity between patients and controls. After resveratrol treatment, no changes in TNFα or IL-8 levels were found, but a significant dose-dependent increase in IL-6 levels was demonstrated in patients with osteoarthritis, but not controls. Sirt1 activity did not correlate with clinical activity (Lequesne’s index) or inflammation (erythrocyte sedimentation rate, C-reactive protein). Conclusion Sirt1 activity (cytoplasmic and nuclear) from peripheral blood mononuclear cells did not differ between patients with osteoarthritis and controls. Ex vivo treatment of peripheral blood mononuclear cells with resveratrol was associated with a dose-dependent increase in IL-6 levels only in patients with osteoarthritis.